Sciars (458870.KQ), a wearable artificial intelligence (AI) diagnostic monitoring company, announced Wednesday that it has signed a memorandum of understanding (MOU) with Samsung Fire & Marine Insurance to build a mid- to long-term healthcare cooperation model and jointly pursue an integrated digital healthcare platform business that includes post-discharge patient management and prognosis prediction.
The agreement was designed to combine Samsung Fire & Marine Insurance's insurance data with Sciars' AI-based digital monitoring technology to develop aftercare services for post-discharge patients, build disease prognosis prediction models and establish an integrated digital care platform.
The two companies plan to build an "aftercare service platform" by leveraging the diverse customer cohort-based data held by the insurer and Sciars' wearable AI-based full-cycle patient monitoring system. Through this, they plan to manage customers' health conditions more continuously and precisely, and implement integrated healthcare services that extend to severity prevention and prediction, recovery management and support for return to daily life.
According to the company, the cooperation is significant in that it expands the role of insurance beyond after-the-fact compensation to preventing and managing customers' health risks in advance, and supporting recovery and care. A Sciars official said, "Samsung Fire & Marine Insurance's selection of Sciars as a strategic partner in the AI-based digital healthcare field reflects an intent to connect Sciars' validated hospital-centered diagnostic and monitoring technology with post-discharge home health management to implement true full-cycle patient care services."
Sciars has also continuously expanded its business foundation in the post-hospital patient management area through various clinical and service references, including cancer patient management cooperation and the establishment of home medical care-based patient management models. The company plans to develop the model into a full-fledged home medical care commercialization stage by linking it with insurance services.
Sciars holds digital biomarker-based technology that can continuously measure and analyze patients' biosignals, based on real-world data accumulated through its inpatient monitoring platform "thynC™" and its AI analysis capabilities. This technology is structured to expand beyond in-hospital patient monitoring to post-discharge patient management and aftercare services.
Based on this, the two companies plan to develop a joint commercialization model through an integrated care platform that combines insurance data with various medical data, including biosignals, going beyond simple technology cooperation. The patient management system, currently centered on diagnosis and monitoring, is expected to expand into prediction- and prevention-oriented healthcare services.
"This cooperation is the starting point for building an integrated model that connects post-discharge patient management and prognosis prediction, based on the data analysis capabilities and operational experience accumulated in in-hospital patient monitoring," Sciars CEO Lee Young-shin said. "We will validate the full-cycle patient integrated platform linked with insurers and expand into global markets based on this."
Meanwhile, Sciars has been setting record quarterly results driven by its AI-based inpatient monitoring platform "thynC." In the first quarter of this year, the company posted consolidated revenue of 32.5 billion won and operating profit of 13.9 billion won. Revenue rose 700% year-on-year, and operating profit turned positive.
